Johnson & Johnson (NYSE:JNJ) Shares Purchased by Chicago Capital LLC

Chicago Capital LLC raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 61,647 shares of the company's stock after buying an additional 5,308 shares during the quarter. Chicago Capital LLC's holdings in Johnson & Johnson were worth $10,223,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Consilium Wealth Advisory LLC grew its holdings in Johnson & Johnson by 62.0% during the first quarter. Consilium Wealth Advisory LLC now owns 8,294 shares of the company's stock worth $1,375,000 after acquiring an additional 3,175 shares during the period. BCU Wealth Advisors LLC purchased a new position in Johnson & Johnson during the 1st quarter worth approximately $208,000. Inscription Capital LLC acquired a new stake in Johnson & Johnson during the 1st quarter valued at $3,863,000. Blackston Financial Advisory Group LLC lifted its holdings in shares of Johnson & Johnson by 7.3% in the first quarter. Blackston Financial Advisory Group LLC now owns 5,262 shares of the company's stock valued at $873,000 after purchasing an additional 360 shares in the last quarter. Finally, Stephens Consulting LLC lifted its stake in Johnson & Johnson by 13.8% in the 1st quarter. Stephens Consulting LLC now owns 4,714 shares of the company's stock worth $782,000 after acquiring an additional 571 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $152.38 on Wednesday. The firm has a market capitalization of $366.65 billion, a PE ratio of 16.95, a price-to-earnings-growth ratio of 2.35 and a beta of 0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm has a 50-day moving average price of $154.03 and a 200 day moving average price of $153.69.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on JNJ shares. Bank of America decreased their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Barclays decreased their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.